Stanley Satz, Ph.D., Chief Science Officer & Chairman

A radiation physicist with more than 40 years of experience and an expert in the development of radiopharmaceuticals for tumor targeted radiation therapy, Satz’s coordination chemistry studies have enabled the synthesis of novel small molecules that have been translated from pre-clinical to clinical use for pediatric diseases and breast cancer.

​

Roseanne Satz, Chief Executive Officer

With over 20 years of leadership in radiopharmaceuticals, Ms. Satz's management, regulatory, and production efforts have resulted in multiple FDA approvals. Her network of clinicians, scientists, research organizations, and manufacturing partners allows AIP to efficiently develop, launch, and supply its pharmaceutical candidates.